The Experts below are selected from a list of 288 Experts worldwide ranked by ideXlab platform
Litao Yang - One of the best experts on this subject based on the ideXlab platform.
-
mini disk capillary array coupling with lamp for visual detection of multiple nucleic acids using Genetically Modified Organism analysis as an example
Journal of Agricultural and Food Chemistry, 2020Co-Authors: Rong Li, Jianwei Chen, Xiujie Zhang, Litao YangAbstract:Convenient, portable, and low-cost multiplex nucleic acid testing (NAT) systems are the trends in the fields of food safety, environmental microOrganisms, molecular diagnosis, etc. In this study, w...
-
collaborative ring trial of the papaya endogenous reference gene and its polymerase chain reaction assays for Genetically Modified Organism analysis
Journal of Agricultural and Food Chemistry, 2013Co-Authors: Feiwu Li, Xiang Li, Junfeng Xu, Gang Wu, Dabing Zhang, Litao YangAbstract:The papaya (Carica papaya L.) Chymopapain (CHY) gene has been reported as a suitable endogenous reference gene for Genetically Modified (GM) papaya detection in previous studies. Herein, we further validated the use of the CHY gene and its qualitative and quantitative polymerase chain reaction (PCR) assays through an interlaboratory collaborative ring trial. A total of 12 laboratories working on detection of Genetically Modified Organisms participated in the ring trial and returned test results. Statistical analysis of the returned results confirmed the species specificity, low heterogeneity, and single-copy number of the CHY gene among different papaya varieties. The limit of detection of the CHY qualitative PCR assay was 0.1%, while the limit of quantification of the quantitative PCR assay was ∼25 copies of haploid papaya genome with acceptable PCR efficiency and linearity. The differences between the tested and true values of papaya content in 10 blind samples ranged from 0.84 to 6.58%. These results i...
A P Hospersgeke - One of the best experts on this subject based on the ideXlab platform.
-
off label prescription of Genetically Modified Organism medicines in europe emerging conflicts of interest
Human Gene Therapy, 2014Co-Authors: H E Schagenfrederik, C Hoebenrob, A P HospersgekeAbstract:Abstract Recently, the first human medicine containing a Genetically Modified Organism (GMO medicine) was authorized for use in the European market. Just as any medicinal product, the market authorization for a GMO medicine contains a precise description of the therapeutic use for which the medicinal product is intended. Within this use, the application of the GMO medicine is permitted, without the need for the institution to obtain a specific permit. In practice, however, medicinal products are also frequently prescribed for treatment outside the registered therapeutic use, a practice that is referred to as “off-label use.” While off-label use of conventional medicines is permitted and has been very useful, the off-label use of GMO medicines is not covered in the European Union (EU) legislation or guidelines and falls under each member state's national environmental legislation. This implies that in the Netherlands and most other EU member states, an environmental permit will be required for any institut...
Geke A P Hospers - One of the best experts on this subject based on the ideXlab platform.
-
off label prescription of Genetically Modified Organism medicines in europe emerging conflicts of interest
Human Gene Therapy, 2014Co-Authors: Frederik H E Schagen, Rob C Hoeben, Geke A P HospersAbstract:Recently, the first human medicine containing a Genetically Modified Organism (GMO medicine) was authorized for use in the European market. Just as any medicinal product, the market authorization for a GMO medicine contains a precise description of the therapeutic use for which the medicinal product is intended. Within this use, the application of the GMO medicine is permitted, without the need for the institution to obtain a specific permit. In practice, however, medicinal products are also frequently prescribed for treatment outside the registered therapeutic use, a practice that is referred to as "off-label use." While off-label use of conventional medicines is permitted and has been very useful, the off-label use of GMO medicines is not covered in the European Union (EU) legislation or guidelines and falls under each member state's national environmental legislation. This implies that in the Netherlands and most other EU member states, an environmental permit will be required for any institution that uses the GMO medicine outside the registered application(s). In the Netherlands, this permit is identical to the permits required for the execution of clinical trials involving nonregistered GMOs. The application procedure for such permit is time-consuming. This process can therefore limit the therapeutic options for medical professionals. As a consequence, desired treatment regimens could be withheld for certain patient (groups). To make future off-label use of GMO medicines permissible in a way that is acceptable for all stakeholders, regulators should adopt a proactive attitude and formulate transparent legislative procedures for this. Only then the field can maintain the public acceptance of GMO medicines, while maintaining the freedom to operate of medical professionals.
Vishwanath Prasad Agrawal - One of the best experts on this subject based on the ideXlab platform.
-
Genetically Modified Organism gmo and its detection method
Journal of Food Science and Technology Nepal, 2009Co-Authors: Gyan Sundar Sahukhal, Bina Laxmi Jayana, Nirmal Dhungana, Nawa Raj Dahal, Ganesh Dawadi, Shova Shrestha, Vishwanath Prasad AgrawalAbstract:Genetically Modified (GM) crops currently account for 29% of crop production worldwide. Despite a lack of regulations to provide for food labelling that allows for consumer preference, many products carry negative or positive labels with regard to genetic modification . Regulatory demands of labelling and traceability of GMOs in the food chain need suitable sampling protocols and analytical methods. At present, two main techniques, the DNA-based polymerase chain reaction (PCR) and the protein-based enzyme-linked immunosorbent assay (ELISA) are most widely used, although new technologies, such as microarrays, have been also developed. The main objective of this review paper is to assess the detection methods both protein based and PCR based as described by different researchers, which represents the state-of-the-art technique for GMO detection in food. Key words: GMO; Beneficial Aspects; Harmful Aspects; Detection Strategy Journal of Food Science & Technology Nepal Vol 4, September, 2008, Page: 18-22
Lv K - One of the best experts on this subject based on the ideXlab platform.
-
suggestions for perfect long term mechanism of risk communication of agricultural Genetically Modified Organism in china
Journal of Hebei Agricultural Sciences, 2013Co-Authors: Lv KAbstract:Social and economic benefit were increased with the rapid development of technology of agricultural Genetically Modified Organism,meanwhile,improving the risk communication mechanism of agricultural Genetically Modified Organism which suitable for public participation was particularly important. Based on the analysis of the connotation of risk communication of agricultural Genetically Modified Organism, the mode and effect of risk communication of Genetically Modified Organism in foreign countries were introduced and the objective demands for risk communication and interaction mechanism were studied in the paper from different angles, including researcher,governor,public and so on. The suggestions for perfect long-term mechanism of risk communication of agricultural Genetically Modified Organism were proposed to promote the healthy and sustainable development of the industry of agricultural Genetically Modified Organism in China.